The full effect of Medicare Part D, after the initial policy transition period and across the United States Medicare population, remains unclear.
F ive years after its implementation, the Medicare outpatient prescription drug insurance program for disabled and older adults (Medicare Part D) has become a staple of the Medicare system. As of 2010, more than half of the Medicare population (over 28 million of 46 million beneficiaries) had enrolled in the program and over 1576 stand-alone prescription drug plans and Medicare Advantage organizations competed for these enrollees. 1 Medicare Part D has even received its first major revisionFthe gradual phase out between 2010 and 2020 of the no coverage zone known as the "doughnut hole."
To date, there have been more than 60 published evaluations of whether and how much Part D expanded prescription drug coverage, increased use of medications, and decreased out-of-pocket (OOP) costs. 2 However, surprisingly, most of these studies have major methodological limitations. Nationally representative Part D usage data were not available until recently, therefore for the first 4 years of program operation, most of what is known about Part D has come from research using data from pharmacy chains or single health systems. 2 Although informative, these early studies are insufficient, as they include nonrepresentative populations (which cannot be characterized in pharmacy chain data), do not fully capture patient drug usage, and were generally limited to the transitional year, 2006. Rigorous research methods were also often lacking. Approximately two-thirds of the early Part D studies did not use actual Part D data or apply robust longitudinal study designs that controlled for preexisting trends. Some studies compared prescription drug use of Part D enrollees with that of nonPart D enrollees, although adverse selection has been clearly documented in voluntary enrollment. 3 As a result, current estimates of the average impacts of Medicare Part D in its first year of operation span a fairly large range; relative changes in overall OOP drug costs range from a 32% decrease to a 13% increase, whereas relative increases in overall prescription drug fills range from 6% to 44%. [4] [5] [6] [7] [8] [9] With few exceptions, almost none of these studies have provided estimates that can be generalized to the Medicare population or extended beyond the transitional period of 2006. [6] [7] [10] [11] The lack of nationally representative evaluations of Part D is an important gap in current research. Our earlier research on respondent-reported cost-related medication nonadherence suggests that the impact of Part D was neither uniform across the Medicare population nor limited to the first year of implementation. In a national survey of medication nonadherence due to costs, we could find no evidence of relief among vulnerable groups such as the disabled and individuals with multiple chronic conditions in the first year after Part D implementation. Furthermore, between 20% and 26% of at-risk beneficiaries continued reporting major financial burdens or medication nonadherence because of drug costs as late as 2007. 12, 13 The objective of this study is to provide a comprehensive evaluation of drug usage and OOP costs that is generalizable to the entire community-dwelling Medicare population. We report overall trends in prescription drug use and OOP drug costs in the 6 years before and 2 years after implementation of Medicare Part D (the latest data available for prescription drug use and OOP drug costs). Our estimation of the impact of Part D is based on the difference between actual usage data, standardized to baseline population characteristics, and projected results based on historical trends from 2000 to 2005. Subgroup analyses were conducted to detect evidence of any adverse impacts in potentially vulnerable populations, many of whom have not been previously studied in Part D evaluations.
METHODS
The Medicare Current Beneficiary Survey (MCBS) is a continuous face-to-face panel survey of a representative national sample of Medicare beneficiaries conducted by the Center for Medicare and Medicaid Services.
14 Since 1991, the MCBS has provided detailed longitudinal data on annual samples of Medicare beneficiaries with a current sample size of approximately 12,000 community-dwelling and institutionalized elderly and disabled. The rich variety of measures includes demographic information, income, assets, living arrangements, family supports, health status, changes in health status, functioning, health behaviors, health insurance coverage, drug coverage, health services usage (including copayments, deductibles, and noncovered services), and access to medical care.
The sample for the MCBS is drawn from Medicare enrollment records according to a multistage rotating panelsampling plan, with the sample replenished each year. Respondents are interviewed in person 3 times a year using computer-assisted personal interviewing, resulting in very high response rates (initially approximately 85%). The typical MCBS interview lasts approximately 1 hour. Interview cycles begin with the fall interview, which includes demographic and household composition, and health insurance, and health status. The subsequent interviews collect detailed information on health care usage and expenditures. Each respondent is asked to keep a record of insurance statements, receipts, and prescription bottles, to enhance the accuracy of data collection. Our analysis used the Cost and Use files from the MCBS that are the main source of medication use data and are now available through 2007.
Sample
The sample included community-dwelling Medicare enrollees from 2000 through 2007. We excluded institutionalized respondents because prescription drug expenditures are not captured for this population (n = 5882 of 91,855 total person-years in the 8-year Cost and Use survey population). We then excluded individuals who did not respond to the prescription drug use survey or individuals with 3 or fewer months of entitlement (n = 5755) to ensure a reliable timeframe for estimating annual trends. Our annual samples ranged from 11,167 in 2000 to 11,995 in 2007. Accounting for overlapping panels across years of data, the total number of unique individuals in this study was 38,777. For individuals with 4 to 11 months of entitlement in a calendar year, we weighted their data to reflect the partial year contribution (eg, annual observations for a person observed only 4 months were subject to a weight of 0.33). Three-year sample panels were constructed to examine unadjusted changes in medication use within the same individuals included in the survey from 2005 to 2007. Two-year sample panels were also constructed for sensitivity analyses, and results were consistent, therefore they are not reported here.
Study Variables Prescription Fills and OOP Drug Costs
Prescription drug fills and costs were drawn from the MCBS Cost and Use files in all years (2000 to 2007). 15 Beginning in 2006, the MCBS included prescription drug claims for Part D enrollees in addition to self-reported drug use. Our preliminary comparison of 2006 prescription drug fills by data source showed a 16.8% undercount by selfreported drug fills compared with drug claims, which is consistent with a 17.7% undercount found in an earlier validation study using 1999 MCBS data and pharmacy records. 15 For this study, we used only self-reported drug fills to ensure consistency across all study years. By excluding the claimsFonly prescription drug use, our estimates of changes attributable to Part D are not biased by the additional and as yet unvalidated data source. All drug costs were adjusted to 2007 values using the consumer price index to account for inflation.
Prescription Drug Coverage
We ascertained drug coverage either through a "yes" response to the survey question "Does your (supplemental insurance) provide drug coverage," a medication bill provided during the interview documenting third-party payment, or from data in Medicare's administrative files, as in previous reports. 17 We also constructed a measure of changes in drug coverage status between 2005 and 2007 with the following categories: had no drug coverage in all 3 years, gained drug coverage after Part D (2006 or 2007), or had drug coverage in all 3 years. We excluded people who experienced a loss of drug coverage after Part D because of insufficient sample size (n = 37).
Covariates include: age; sex; race and Hispanic ethnicity; geographic residence; disease burden as measured by a count of specific conditions; Medicaid enrollment; income; and general health status. 13, 18 All variables are selfreported by survey respondents, except for sex, Medicaid enrollment, and age, which come from Medicare's administrative files. Self-reported income is known to be underreported, therefore we inflated the income by 20%, as recommended previously, and categorized the adjusted income in relation to the federal poverty levels. 19 Our comparison of the adjusted income categories with those reported in the Current Population Survey showed consistent results.
Statistical Analyses
We described demographic and health characteristics of the MCBS population in 2000 and 2007, weighted to represent the overall population of community-dwelling Medicare beneficiaries. 14 We calculated unadjusted means of prescription drug fills and OOP prescription drug costs with 95% confidence intervals (CIs) from 2000 to 2007.
To model changes in prescription drug fills and OOP drug costs, we used time-series regressions with a first-order autoregressive correlation structure 20 and only pre-Part D data (2000 to 2005). For each outcome, the model contained an intercept and an indicator of the yearly trend. Using parametric bootstrapping techniques, 21 we conducted 10,000 simulations of post-Part D outcome means (2006 and 2007) based on the null hypothesis that the data would follow the previously estimated trend. We then compared the simulated results with the observed results. We created percentile intervals based on the proportion of simulated values that exceeded the observed value (in the case of average prescription drug fills) or fell below the observed value (in the case of average OOP drug costs), assuming a 1-sided test. We repeated these analyses separately in 18 subgroups based on sex, race/ethnicity, geographic residence, poverty status, and morbidity burden, stratified by self-reported health status (excellent to good vs. fair to poor).
Lastly, we repeated these procedures using adjusted outcome means that were standardized to account for changes in characteristics of the study sample between 2000 and 2007. 22, 23 Weights were derived from stratumlevel characteristics of the standard population in 2000 and applied to the subsequent yearly estimates to create expected means, holding demographic characteristics constant. We then tested for differences between the standardized outcome means and our times series estimates.
We conducted all analyses using Stata version 10 (StataCorp LP, College Station, TX) and SAS version 9.2 (SAS Institute Inc, Cary, NC), and the a priori level of statistical significance was P < 0.05. This study was approved by the Human Subjects Committee of Harvard Pilgrim Health Care.
RESULTS

Characteristics of Medicare Beneficiaries, 2000 and 2007
The demographic and health characteristics of the community-dwelling Medicare population between 2000 and 2007 were very stable over time with some exceptions (Table 1 ). There were slight increases in the proportions of nonelderly disabled Medicare beneficiaries and beneficiaries aged 85 years or older. The proportion of beneficiaries with Medicaid coverage grew, as did the proportion in the Table 2 compares the adjusted average changes in prescription drug use and OOP drug costs after implementation of Part D, estimated using time-series regression and population standardization methods. Accounting for historical trends and holding population characteristics constant, we estimated a 1.8 increase (95% CI, 1.1-2.5; P < 0.001) in annual prescription fills per person and a $142 decrease (95% CI, À 182.5-À 103.1; P < 0.001) in annual OOP drug costs per person in the first year after Part D implementation. In the second year, the estimated increase in fills doubled to 3.4 fills above the predicted average (95% CI, 2.7-4.1; P < 0.001) and the decrease in OOP drug costs per persons was sustained at $148 below predicted (95% CI, À 181.2-À 114.1; P < 0.001).
Changes in Study Outcomes for Subgroups of Medicare Beneficiaries, by Health Status
Results from the subgroup analyses are summarized in Figures 2A and B use ranging from 3.7 to 11.0 above estimated levels except for the wealthiest beneficiaries whose observed and predicted levels of prescription use were similar. In comparison, average annual OOP drug costs decreased significantly by $86 to $302 in 2006 over predicted levels across nearly all subgroups of Medicare beneficiaries, regardless of health status, and these decreases were sustained in 2007 (Fig. 2B ). For example, based on historical trends before Part D implementation, the average costs of prescription drugs among dual-eligible Medicaid beneficiaries in excellent-to-good health was predicted to be $256 in 2006. Their actual 2006 average cost was $144 (P < 0.001). Significant decreases in OOP drug costs over predicted levels were experienced by all groups except one, individuals in fair-to-poor health with incomes < 100% FPL who were not enrolled in Medicaid. The year-to-year overlaps in 95% CIs for groups that had consistent drug coverage or consistent lack of coverage suggest that the observed changes in OOP costs for these groups were not significant.
Changes in Study Outcomes for Medicare Beneficiaries by Insurance Status
Comment
Our study found that after the transition year of 2006, the impact of Part D seemed larger and more consistent across the Medicare population. Of note, sick and poor beneficiaries experienced significant improvements in prescription drug use in 2007. As in the earlier studies, we found that the first year of Part D was associated with a modest but significant 6% increase in average prescription drug use over predicted levels (32.8 vs. 31.0) across the overall Medicare community-dwelling population. 2 However, we found a much larger impact in 2007, namely a significant 14% increase in average prescription drug use over predicted levels (35.0 vs. 31.6). Furthermore, the significant 23% decrease in average OOP drug costs over the predicted levels ($618 vs. Our study offers a unique combination of nationally representative data spanning 6 years before and 2 years after the implementation of Part D and a rigorous longitudinal study design. Our use of time-series regressions and standardization weights allowed us to provide robust estimates of Part D impacts, especially after the transitional initial year. This study also offers one of the first assessments of whether the program had consistent impacts across vulnerable poor and chronically ill populations. Using self-reported drug fills to ensure consistency across all study years is another unique feature of this study. Use of self-reported drug fills overcomes several common biases of claims-based studies, including their omission of prescriptions filled at out-of-network pharmacies, free samples, and prescriptions not paid by insurance.
The increases in prescription drug use and decreases in OOP drug costs in the community-dwelling Medicare population are consistent with our earlier findings that selfreported cost-related medication nonadherence significantly decreased in this population after implementation of Part D. 13 We can now support those findings with empirical evidence about similar changes in the actual use of medications and costs. Furthermore, we found no significant increase in medication use after Part D in the sickest segments of the Medicare population until 2007, echoing our earlier finding that the sickest groups reported only lagged improvements in cost-related nonadherence. 13 We postulate that 2006 was a transitional period for 2 reasons. First, the deadline for enrollment in 2006 was delayed to May and thus that year captures partial year effects, as shown by others. 6, 11 Second, there is some evidence that previously uninsured people had to learn to use and optimize the new insurance coverage, especially the first time entering a gap in coverage. 24 Our study has several limitations. The 6 years of prepolicy data provide an important comparison and context for our analyses. However, additional postpolicy years would provide more clarity about the long-term impacts of implementing Part D. MCBS drug usage data after 2007 are not yet available. Certainly, the first year of the new program was a transitional period and results from 2006 may underestimate the true effects of Part D; however, the extent to which 2007 data represent stable effects is still unknown. Other factors unrelated to Part D (such as contemporaneous changes in the financial condition of Medicare beneficiaries) may also have influenced the observed changes in drug use and costs both before and after implementation of Part D. Thus, our results should still be considered early evidence until long-term data are available.
In conclusion, in comparison with historical trends, we found significant population-level increases in prescription drug use and decreases in OOP drug costs in the first and second years after implementation of Medicare Part D. However, some subgroups of beneficiaries in fair-to-poor health experienced only lagged changes in prescription drug use, despite immediate decreases in drug costs. Further research is needed to determine whether essential medications were most affected by implementation of Part D, and whether increased access to those medications impacted health outcomes in nationally representative populations. 
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